|
Jazeera Pharmaceutical Industries ( JPI) is a Saudi pharmaceutical manufacturer. Established in the year 1999, JPI's main objective was to manufacture and market high quality healthcare products at a reasonable cost satisfying patient needs in Saudi Arabia and other neighboring markets. Another collateral objective was to be an active participant in reaching regional self-sufficiency in healthcare products and be an essential contributor in enhancing the nation's economic development.
JPI Locations:
-
Main Scientific Office: New Akareya Building, Salah El Din St., P.O. Box 106229, Riyadh 11666, Saudi Arabia
-
Plant:  South of Riyadh, 3 rd Industrial Zone.
Main Therapeutic Areas:
Anti-infe ctives
Musculo-skeletal
Cardiovascular
Alimentary
Respiratory
Dermatology
Genito-urinary
Key Products:
JPI has more than 110 registered products in Saudi Arabia and around the world. These products are actively present in the leading therapeutic areas.
List of Main Products:
Product |
Active Ingredient |
Omnicef ® |
Cefdinir |
Megamox ® |
Amoxi-Clav |
Penetrex ® |
Enoxacin |
Xefo ® |
Lornoxicam |
Omeral ® |
Omeprazole |
Duspamen ® |
Mebeverine |
Repaderm ® |
Aescin +Diethylamine |
Diclomax ® |
Diclofenac Na |
Cefaxon ® |
Ceftriaxone |
Cefofix ® |
Cefuroxime Na |
S S Cream ® |
Herbal |
Paraxone ® |
Chlorzoxazone + Paracetamol |
Rectacure ® |
Tribenoside + Lidocaine |
Calcichew D3 ® |
Calcium + Vit.D3 |
Zinopril ® |
Lisinopril |
Oflam ® |
Diclofenac K |
Last Update: April 2006
|
|